Navigation Links
TriReme Medical Inc. Receives CE Marking for Antares(TM) Coronary Stent System
Date:10/10/2008

PLEASANTON, Calif., Oct. 10 /PRNewswire/ -- TriReme Medical Inc. (TMI) announced today that it has been authorized to affix the CE (Conformite Europeenne) marking and commercialize in Europe the Antares(TM) Coronary Stent System, a unique main vessel stent system specially designed for use at or near coronary bifurcations.

Representing the next generation in bifurcation stenting, the Antares(TM) system has potential use in a quarter of the 2.2 million angioplasty procedures performed annually worldwide. Antares(TM) stents are not yet approved in the United States and are limited by Federal law to investigational use.

"We are very pleased to achieve this significant milestone that allows commercialization of our Antares(TM) stent system in Europe," said Eitan Konstantino, PhD, President and Chief Executive Officer of TMI. "We believe that the Antares(TM) stent system represents a breakthrough in the treatment of patients suffering from coronary artery disease at or near bifurcations.

"I like the Antares(TM) system concept. The system is designed to fit all classes of bifurcation lesions, irrespective of the size and angulation of the side-branch," said Professor Carlo Di Mario from Royal Brompton Hospital in London. "The operator does not need to commit to a pre-determined side branch treatment and has the flexibility to do what is right for the patient."

Lesions at or near side branches in the coronary tree pose multiple challenges to interventional cardiologists. Combining a low profile stent with a proprietary delivery system, the Antares(TM) system provides a unique set of solutions to the challenges of bifurcation stenting. It can be delivered and deployed in a single step while maintaining access to the side branch and scaffolding the ostium, or the origin of the side branch. As a result, the cardiologist has greater flexibility of treatment options, with the freedom to deploy a second stent in the side branch when additional support is necessary.

"The Antares(TM) stent system is an elegant solution to treat bifurcation lesions that is focused on the main vessel," observed Alexandre Abizaid, MD, PhD, Chief of Coronary Interventions at the Institute Dante Pazzanese of Cardiology in Sao Paulo, Brazil. Dr. Abizaid continued, "It increases operators' confidence by providing continuous side branch access throughout the procedure."

About TriReme Medical Inc.

TriReme Medical Inc. (TMI) is a privately held medical device company backed by Three Arch Partners and Adams Street Partners. TMI is based in California and dedicated to the development and manufacturing of novel stent technology for the treatment of atherosclerotic disease at or near bifurcations.


'/>"/>
SOURCE TriReme Medical Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
2. You May Have a Thyroid Problem and Not Know It - Particularly If Youre Over 60, Says a New Harvard Medical School Report
3. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
4. Globus Medical Raises $110 Million in Series E Financing Round
5. Quark Pharmaceuticals Appoints New Chief Medical Officer
6. Boston University Biomedical Engineers Find Chink in Bacterias Armor
7. Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial
8. Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study
9. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials
10. Cleveland Clinic Summits to Focus on Cardiovascular Medical Innovation
11. Rockwell Medical Technologies, Inc. Begins Dosing Patients for SFP Phase IIb Clinical Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... Research and Markets has announced the addition of the "Deep ... to their offering. ... The Deep Learning: Drug Discovery and Diagnostics Market, 2017-2035 report examines ... deep learning solutions within the healthcare domain. Primarily driven by the ... solution to generate relevant insights from medical data. ...
(Date:3/24/2017)... YORK , March 24, 2017 ... and Equipment stocks, which are: Neovasc Inc. (NASDAQ: NVCN), Hologic ... Heart Inc. (NASDAQ: SSH ). These companies are ... its prior gains on Thursday, March 23 rd , 2017, ... afternoon, while shares of health care companies in the S&P ...
(Date:3/24/2017)...  Eli Lilly and Company (NYSE: ... million in its U.S. operations in 2017. The ... including research laboratories, manufacturing sites, and general and ... demand for Lilly products, as well as its ... cancer, pain, diabetes and other unmet medical needs.  ...
Breaking Medicine Technology:
(Date:3/24/2017)... MN (PRWEB) , ... March 24, 2017 , ... ... back to the military at the same time by providing Prehospital Trauma Life ... Guard. PHTLS is the world’s premier prehospital trauma education developed in cooperation with ...
(Date:3/24/2017)... , ... March 24, 2017 , ... According to a ... is invalid because it does not obey the rules Congress has directed the CBO ... jobs, which the GOP reform would restore. Yet, it estimates a reduction in employer-based ...
(Date:3/24/2017)... San Diego, Calif. (PRWEB) , ... March 24, ... ... (ADI) has raised over $100,000 for its innovative EcoQube Frame vertical micro-veggies garden ... demonstrates the instant demand for the product – with nearly 2,000 consumers (and ...
(Date:3/24/2017)... ... March 24, 2017 , ... Viewers who like to educate themselves on ... cultural practices, goods, services, and societal issues tend to appreciate and love the "Informed" ... practice of utilizing running events for causes around the world. , Running ...
(Date:3/24/2017)... , ... March 24, 2017 , ... “End Time GPS”: ... salient events will interrelate. “End Time GPS” is the creation of published author, ... expert while working on military munitions and space-vehicle projects. Now, at age ninety-one, he ...
Breaking Medicine News(10 mins):